retatrutide triple agonist obesity phase 2 trial Number 1 Top Cardiometabolic Story of 2023: with #retatrutide, a GIP-GLP-1-GCG receptor agonist, resulted in a mean weight reduction of 24.2% after 48 weeks. https://t.co/aED6xEFDI3 retatrutide triple agonist glp-1 gip

Losing excess weight may reduce inflammation, improve energy, reduce joint strain, improve blood pressure, and lower the risk of diabetes and heart disease

Tell your healthcare provider if you are taking other medicines to treat diabetes, including insulin and sulfonylureas, because the combination may exacerbate low blood sugar (glucose) levels

RMID:Image ID:3DJE4Y7 Image details Contributor: Richard Levine Image ID: 3DJE4Y7 File size: 54 MB (1.8 MB Compressed download) Releases: Model - no | Property - noDo I need a release

This transition encourages a sustainable relationship with food, promoting a continuum of weight management and overall metabolic health long after the pharmacological intervention has concluded